title: Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
abstract: BACKGROUND
  Arginine vasopressin (AVP) levels are elevated in proportion to heart failure severity and are associated with higher cardiovascular mortality in ambulatory patients. However, the relationship between baseline and trends in AVP with outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction is unclear.
  
  
  RESULTS
  The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial investigated the effects of tolvaptan in patients with worsening heart failure and ejection fraction ≤40%. The present analysis examined baseline and follow-up AVP levels in 3196 EVEREST patients with valid AVP measurements. Coprimary end points included all-cause mortality, and the composite of cardiovascular mortality or heart failure hospitalization. Median follow-up was 9.9 months. Times to events were compared with univariate log-rank tests and multivariable Cox regression models, adjusted for baseline risk factors. After adjusting for baseline covariates, elevated AVP levels were associated with increased all-cause mortality (hazard ratio, 1.33; 95% confidence interval, 1.13-1.55) and cardiovascular mortality or heart failure hospitalization (hazard ratio, 1.23; 95% confidence interval, 1.08-1.39). There was no interaction of baseline AVP with treatment assignment in terms of survival (P=0.515). Tolvaptan therapy increased the proportion of patients with elevated AVP (P<0.001), but this had no effect on mortality (hazard ratio, 0.95; 95% confidence interval, 0.72-1.24).
  
  
  CONCLUSIONS
  Elevated baseline AVP level was independently predictive of mortality, but did not identify a group of patients who had improved outcomes with tolvaptan treatment. Tolvaptan treatment increased AVP levels during follow-up, but this incremental increase was not associated with worsened outcomes.
authors.affiliation: Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Lanfear
authors.forename: Hani N
authors.initials: HN
authors.lastname: Sabbah
authors.forename: Steven R
authors.initials: SR
authors.lastname: Goldsmith
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Greene
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Ambrosy
authors.forename: Angela J
authors.initials: AJ
authors.lastname: Fought
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Kwasny
authors.forename: Karl
authors.initials: K
authors.lastname: Swedberg
authors.forename: Clyde W
authors.initials: CW
authors.lastname: Yancy
authors.forename: Marvin A
authors.initials: MA
authors.lastname: Konstam
authors.forename: Aldo P
authors.initials: AP
authors.lastname: Maggioni
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
mesh_terms: D000368:Aged; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000097:blood*; D001552:Benzazepines / Q000627:therapeutic use*; D002423:Cause of Death / Q000639:trends; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007297:Inpatients; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology*; D015996:Survival Rate / Q000639:trends; D000077602:Tolvaptan; D014481:United States / Q000453:epidemiology
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D001127:Arginine Vasopressin; D000077602:Tolvaptan